Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Femborra is a brand of over-the-counter (OTC) feminine care products developed and marketed by Amato Pharmaceutical Products, a Japanese company specializing in hemorrhoid and topical treatments. The Femborra line includes a Class 2 OTC drug indicated for the relief of itching, inflammation, and rashes in the delicate feminine area. The therapeutic formulation typically combines diphenhydramine hydrochloride (an antihistamine), lidocaine (a local anesthetic), isopropylmethylphenol (an antiseptic), and tocopherol acetate (Vitamin E). These ingredients work synergistically to suppress itching, provide rapid pain relief, inhibit bacterial growth, and promote skin repair through improved microcirculation. The brand also encompasses non-medicinal hygiene products such as cleansing mists and moisturizing milks designed for feminine hygiene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Femborra.